Novartis Raises 2026 Core Operating Income Outlook After Q3 Core EPS Rises 9%
Photo: TokenPost
Novartis raised its 2026 core operating income outlook after third-quarter core earnings per share rose 9% year over year to $2.46. The Swiss drugmaker’s net sales also increased, while reported operating income and net income declined sharply in the quarter ended Sept. 30. Core operating income reached $6.036 billion, up 11% in reported dollars and 10% at constant currencies. Core EPS increased from $2.25 a year earlier; its growth was 8% at constant currencies. Novartis classifies core results as non-IFRS measures. For 2026, Novartis sees core operating income holding at 2025 levels or posting low-single-digit growth on a constant-currency basis.
Source: TokenPost
